Aslan Stock Leadership

ASLN -  USA Stock  

USD 1.30  0.14  9.72%

Aslan Pharmaceuticals employes about 18 people. The company is managed by 14 executives with total tenure of roughly 73 years, averaging almost 5.0 years of service per executive having 1.29 employees per reported executive. Inspection of Aslan Pharmaceuticals management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Aslan Pharmaceuticals future performance.
Please continue to Trending Equities.

Aslan Insiders 

  Carl Firth  Chairman
Chairman of the Board, CEO
  Kiran Asarpota  President
Vice President-Finance

Aslan Pharmaceuticals Return on Sales


Aslan Pharmaceuticals Management Team Effectiveness

Aslan Pharmaceuticals has return on total asset (ROA) of (20.58) % which means that it has lost $20.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (53.74) %, meaning that it created substantial loss on money invested by shareholders. Aslan Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is expected to rise to 2.03 this year, although the value of Return on Average Assets will most likely fall to (1.17) . Aslan Pharmaceuticals Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 16 Million. Tangible Asset Value is expected to rise to about 23.1 M this year, although the value of Asset Turnover will most likely fall to 0.07.

Aslan Pharmaceuticals Quarterly Total Assets

104.85 MillionShare
Weighted Average Shares is expected to rise to about 198.4 M this year. Weighted Average Shares Diluted is expected to rise to about 198.5 M this year

Aslan Pharmaceuticals Workforce Comparison

Aslan Pharmaceuticals is rated second in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 67.0. Aslan Pharmaceuticals totals roughly 18.0 in number of employees claiming about 27% of stocks in Biotechnology industry.

Aslan Pharmaceuticals Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Aslan Pharmaceuticals Price Series Multiplication is a cross multiplication of Aslan Pharmaceuticals price series and its benchmark/peer. View also all equity analysis or get more info about price series multiplication math operators indicator.

Aslan Pharmaceuticals Notable Stakeholders

An Aslan Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aslan Pharmaceuticals often face trade-offs trying to please all of them. Aslan Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aslan Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Carl Firth - Chairman of the Board, CEOProfile
Kiran Asarpota - Vice President-FinanceProfile
Mark McHale - COOProfile
Qingfeng Sun - Independent DirectorProfile
Damien Lim - DirectorProfile
Abel Ang - DirectorProfile
ChinFeng Sun - Independent DirectorProfile
Jun Wu - DirectorProfile
Meishu Lai - Independent DirectorProfile
Andrew Howden - Independent DirectorProfile
Zhilong Shen - DirectorProfile
Robert Hoffman - Independent DirectorProfile
Bertil Lindmark - Chief Medical OfficerProfile
Zhiyi Xie - Chief Medical OfficerProfile

About Aslan Pharmaceuticals Management Performance

The success or failure of an entity such as Aslan Pharmaceuticals often depends on how effective the management is. Aslan Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aslan management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aslan management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Average Assets(1.09) (1.17) 
Return on Average Equity 1.89  2.03 
Return on Invested Capital(1.15) (1.23) 
Return on Sales(13.73) (14.09) 
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people.
The data published in Aslan Pharmaceuticals' official financial statements usually reflect Aslan Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Aslan Pharmaceuticals. For example, before you start analyzing numbers published by Aslan accountants, it's critical to develop an understanding of what Aslan Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Aslan Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aslan Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Aslan Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aslan Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Aslan Pharmaceuticals' management to manipulate its earnings.

Aslan Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Aslan Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aslan Pharmaceuticals within its industry.

Aslan Pharmaceuticals Manpower Efficiency

Return on Aslan Pharmaceuticals Manpower

Revenue Per Employee10.5 K
Revenue Per Executive13.6 K
Net Loss Per Employee1.1 M
Net Loss Per Executive1.4 M
Working Capital Per Employee2.7 M
Working Capital Per Executive3.5 M
Please continue to Trending Equities. Note that the Aslan Pharmaceuticals information on this page should be used as a complementary analysis to other Aslan Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Aslan Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.